Media

As a sponsor of the CHCI Health Summit, Immunomic Therapeutics is pleased to support the initiatives of the event which include attracting and retaining greater diversity in clinical trials, ensuring

February 28, 2019 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that a poster will be presented by Immunomic scientists at the American Association for Cancer

Immunomic Therapeutics to Sponsor and Present at CHCI Health Summit February 26, 2019 04:05 PM Eastern Standard Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its’ Senior Vice

  February 06, 2019 05:00 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company has granted Japanese animal

January 24, 2019 04:05 PM Eastern Standard Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its’ founder and CEO, William Hearl, Ph.D., will present an overview of the

November 15, 2018 06:15 AM Eastern Standard Time SAN DIEGO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) announced today that the company will present and participate at the 2018 World Vaccine & Immunotherapy

November 07, 2018 06:00 AM Eastern Standard Time NEW ORLEANS--(BUSINESS WIRE)--On Friday, November 16, Immunomic Therapeutics Inc. (ITI) Scientist Amit Adhikara will present at the Society for NeuroOncology 2018 Annual

ITI's Michael Connolly, Manager of Process Development, presents a poster titled, "Functional evaluation of isoforms present in pDNA vaccines" at Aldevron's corporate offices located in Fargo, North Dakota A detailed abstract

The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to

Reporting on Rapid Advancements of Clinical, Scientific and Business Developments in IO Immuno-Oncology 360° addresses business aspects, clinical advancements and scientific data for cancer immunotherapy that helps advance technology platforms

2019 J.P. Morgan Health Care Investor Conference January 6 - 10, 2019 The Annual J.P. Morgan Healthcare Conference will take place January 6-10, 2019. This event continues to be one of